Free Trial

Mirador Capital Partners LP Raises Holdings in Celldex Therapeutics, Inc. $CLDX

Celldex Therapeutics logo with Medical background

Key Points

  • Mirador Capital Partners LP increased its stake in Celldex Therapeutics by 24.1% during the second quarter, owning 158,717 shares worth approximately $3.23 million.
  • Celldex Therapeutics reported a quarterly earnings per share of ($0.85), beating the consensus estimate by $0.01, but had significantly lower revenue than expected at $0.73 million.
  • Analysts have downgraded price targets for Celldex Therapeutics, with HC Wainwright lowering theirs from $50.00 to $42.00, maintaining a "buy" rating on the stock.
  • Interested in Celldex Therapeutics? Here are five stocks we like better.

Mirador Capital Partners LP increased its stake in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 24.1% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 158,717 shares of the biopharmaceutical company's stock after purchasing an additional 30,843 shares during the quarter. Mirador Capital Partners LP owned approximately 0.24% of Celldex Therapeutics worth $3,230,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in CLDX. Nuveen LLC purchased a new stake in Celldex Therapeutics in the first quarter valued at about $7,789,000. Millennium Management LLC raised its stake in Celldex Therapeutics by 327.3% in the first quarter. Millennium Management LLC now owns 399,932 shares of the biopharmaceutical company's stock valued at $7,259,000 after buying an additional 306,330 shares during the last quarter. TFG Asset Management GP Ltd purchased a new stake in Celldex Therapeutics in the fourth quarter valued at about $4,852,000. Polar Asset Management Partners Inc. raised its stake in Celldex Therapeutics by 1,318.0% in the fourth quarter. Polar Asset Management Partners Inc. now owns 137,550 shares of the biopharmaceutical company's stock valued at $3,476,000 after buying an additional 127,850 shares during the last quarter. Finally, Deutsche Bank AG raised its stake in Celldex Therapeutics by 207.9% in the fourth quarter. Deutsche Bank AG now owns 121,501 shares of the biopharmaceutical company's stock valued at $3,070,000 after buying an additional 82,042 shares during the last quarter.

Celldex Therapeutics Stock Performance

Shares of Celldex Therapeutics stock traded down $1.31 during trading hours on Friday, hitting $24.61. The company's stock had a trading volume of 2,473,738 shares, compared to its average volume of 1,381,859. Celldex Therapeutics, Inc. has a twelve month low of $14.40 and a twelve month high of $47.00. The firm has a fifty day moving average of $23.02 and a 200-day moving average of $20.89. The stock has a market cap of $1.63 billion, a price-to-earnings ratio of -8.18 and a beta of 1.19.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported ($0.85) EPS for the quarter, beating the consensus estimate of ($0.86) by $0.01. Celldex Therapeutics had a negative return on equity of 27.61% and a negative net margin of 3,446.88%.The business had revenue of $0.73 million for the quarter, compared to analyst estimates of $1.13 million. On average, sell-side analysts expect that Celldex Therapeutics, Inc. will post -2.48 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on the company. Citigroup decreased their price target on Celldex Therapeutics from $56.00 to $48.00 and set a "buy" rating for the company in a research note on Wednesday, August 20th. Canaccord Genuity Group reissued a "buy" rating and issued a $62.00 price objective on shares of Celldex Therapeutics in a report on Wednesday. HC Wainwright cut their price objective on Celldex Therapeutics from $50.00 to $42.00 and set a "buy" rating on the stock in a report on Wednesday, August 20th. Finally, Wells Fargo & Company cut their price objective on Celldex Therapeutics from $44.00 to $38.00 and set an "overweight" rating on the stock in a report on Wednesday, August 20th. Seven equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company's stock. Based on data from MarketBeat, Celldex Therapeutics presently has a consensus rating of "Moderate Buy" and an average target price of $46.67.

Check Out Our Latest Analysis on CLDX

About Celldex Therapeutics

(Free Report)

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.

Further Reading

Institutional Ownership by Quarter for Celldex Therapeutics (NASDAQ:CLDX)

Should You Invest $1,000 in Celldex Therapeutics Right Now?

Before you consider Celldex Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Celldex Therapeutics wasn't on the list.

While Celldex Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report
Like this article? Share it with a colleague.